Optimizing Cancer Care Delivery: Capacity and Cost Benefits of Home-Based Self-Administration of Subcutaneous Trastuzumab
Optimierung der Krebsversorgung: Kapazitäts- und Kostenvorteile der häuslichen Selbstapplikation von subkutanem Trastuzumab
JCO Oncology Practice · 03.11.2026
DOI: 10.1200/op-26-00660 ↗Auf einen Blick
Die häusliche Selbstapplikation von subkutanem Trastuzumab war mit weniger Zeitaufwand für Patient:innen und HCP sowie mit niedrigeren Kosten verbunden als die Krankenhausgabe.
Fragestellung
Wie unterscheiden sich Kosten und Ressourceneinsatz bei subkutanem Trastuzumab zwischen onkologischer Tagesklinik und häuslicher Selbstapplikation?
Methode
Querschnittsstudie, nicht interventionell, mit Mikrokostenansatz; Datenerhebung zu Zeitaufwand, HCP-Beteiligung, Patienten- und gesellschaftlichen Kosten sowie Präferenzen.
Ergebnisse
Pro Gabe reduzierte sich die Patientenzeit um 74,3 Minuten und die HCP-Zeit um 29,9 Minuten. Kosten ohne Arzneimittel: €35.72 vs. €61.61; gesellschaftliche Kosten: €24.86 vs. €39.37. 23 von 25 bevorzugten die häusliche Selbstapplikation.
Schlussfolgerung der Autor:innen
Die häusliche Selbstapplikation von SC Trastuzumab war mit geringerem Zeitaufwand und niedrigeren administrativen sowie gesellschaftlichen Kosten verbunden als die Krankenhausgabe.
Kernaussagen
- 74,3 Minuten weniger Patientenzeit pro Gabe
- 29,9 Minuten weniger HCP-Zeit pro Gabe
- Niedrigere Kosten und hohe Präferenz für die häusliche Anwendung
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, online erschienen am 03.11.2026. Verfasst von Michiel Zietse und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands. Die Arbeit nennt 36 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Self-administration of subcutaneous (SC) monoclonal antibodies offers a potential strategy to mitigate capacity constraints and nurse shortages in oncology care. This study aimed to evaluate the costs and resource use associated with SC trastuzumab administration in oncology daycare units and home-based self-administration from a societal perspective. Materials and Methods We conducted a cross-sectional, noninterventional study using a microcosting approach. Patients receiving home-based self-administration were recruited from the Spaarne Gasthuis, Hoofddorp, the Netherlands, whereas hospital-based administration was based on previously published data. Data were collected on time spent on administration, health care professional (HCP) involvement, patient and societal costs, and patient preferences.
Results
Home-based self-administration reduced patient time by 74.3 minutes (86.9%) and HCP time by 29.9 minutes (87.4%) per administration. Administration costs (excluding drug costs) were €35.72 for self-administration versus €61.61 for hospital-based administration, a €25.89 reduction (–42%). Societal costs were €24.86 for self-administration and €39.37 for hospital-based, saving €14.51 (–37%). Of the 25 patients who completed the preference questionnaire, 23 (92%) preferred home-based self-administration. In a hypothetical nationwide scenario with 90% uptake of home-based self-administration in the Netherlands, this model could save 21,323 hours of patient chair time, reduce HCP time by 12 full-time equivalents, and save €1,510,656 in administration costs and €543,815 in societal costs.
Conclusion
Home-based self-administration of SC trastuzumab was associated with reduced time investments for HCPs and patients, and with lower administration and societal costs than hospital-based administration. These findings highlight the potential of home-based self-administration as an efficient model to alleviate the strain on oncology care.
Autor:innen und Institutionen
- Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, the Netherlands.
- Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, the Netherlands.
- Department of Internal Medicine, Alrijne Hospital, Leiderdorp, the Netherlands.
- Department of Hospital Pharmacy, Spaarne Gasthuis, Hoofddorp, the Netherlands.
- Department of Medical Oncology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
- Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, the Netherlands.
ORCID-Profile: Michiel Zietse, Jaimy R D Raijmaakers, Leontine E A M M Spierings, Tim A Kanters, Ron H J Mathijssen, Frederick W Thielen
Zitieren
APA
Zietse, M., Raijmaakers, J. R. D., Beeker, A., Spierings, L. E. A. M. M., Giezen, T. J., Jager, A., Kanters, T. A., Koch, B. C. P., Mathijssen, R. H. J., Thielen, F. W., & van Leeuwen, R. W. F. (2026). Optimizing Cancer Care Delivery: Capacity and Cost Benefits of Home-Based Self-Administration of Subcutaneous Trastuzumab. JCO Oncology Practice. https://doi.org/10.1200/op-26-00660
Vancouver
Zietse M, Raijmaakers JRD, Beeker A, Spierings LEAMM, Giezen TJ, Jager A, et al. Optimizing Cancer Care Delivery: Capacity and Cost Benefits of Home-Based Self-Administration of Subcutaneous Trastuzumab. JCO Oncology Practice. 2026. doi:10.1200/op-26-00660
BibTeX
@article{Zietse2026,
author = {Zietse, Michiel and Raijmaakers, Jaimy R D and Beeker, Aart and Spierings, Leontine E A M M and Giezen, Thijs J and Jager, Agnes and Kanters, Tim A and Koch, Birgit C P and Mathijssen, Ron H J and Thielen, Frederick W and van Leeuwen, Roelof W F},
title = {Optimizing Cancer Care Delivery: Capacity and Cost Benefits of Home-Based Self-Administration of Subcutaneous Trastuzumab},
journal = {JCO Oncology Practice},
year = {2026},
doi = {10.1200/op-26-00660}
}
EUVIMED